Characteristics of menstrual vs nonmenstrual migraine: A post hoc, within-woman analysis of the usual-care phase of a nonrandomized menstrual migraine clinical trial

Headache

Volumn 50, Issue 4, 2010, Pages 528-538

  MacGregor, E Anne ^a   Victor, Timothy W ^b   Hu, Xiaojun ^b   Xiang, Qinfang ^b   Puenpatom, Rajitkanok A ^b   Chen, Wei ^b   Campbell, John C ^b  

^a City of London Migraine Clinic   (United Kingdom)

^b ENDO PHARMACEUTICALS INC   (United States)

Author keywords

Acute; Menstrual migraine; Migraine; Migraine relapse; Triptan

Indexed keywords

ALMOTRIPTAN; ELETRIPTAN; FROVATRIPTAN; NARATRIPTAN; RIZATRIPTAN; SUMATRIPTAN; TRIPTAN DERIVATIVE; ZOLMITRIPTAN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FUNCTIONAL DISEASE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MATHEMATICAL ANALYSIS; MEDICAL PRACTICE; MENSTRUAL CYCLE; MENSTRUAL MIGRAINE; MIGRAINE; MULTICENTER STUDY; OPEN STUDY; PAIN ASSESSMENT; POST HOC ANALYSIS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RELAPSE; SELF REPORT; UNITED STATES; WOMEN'S HEALTH;

ADMINISTRATION, ORAL; ADULT; AGE OF ONSET; ANALGESICS; COMORBIDITY; DISABILITY EVALUATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MENSTRUATION DISTURBANCES; MIDDLE AGED; MIGRAINE DISORDERS; OUTCOME ASSESSMENT (HEALTH CARE); PAIN MEASUREMENT; PATIENT SATISFACTION; PREMENSTRUAL SYNDROME; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RECURRENCE; SELF ADMINISTRATION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TRYPTAMINES;

EID: 77950542284     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2010.01625.x     Document Type: Article

References (26)

1. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007 68 : 343 349.
2. Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J, Lipton RB. The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia. 2003 23 : 519 527.
3. Stovner LJ, Zwart JA, Hagen K, Terwindt GM, Pascual J. Epidemiology of headache in Europe. Eur J Neurol. 2006 13 : 333 345.
4. Stewart W, Wood C, Reed M, Roy J, Lipton R. Cumulative lifetime migraine incidence in women and men. Cephalalgia. 2008 28 : 1170 1178.
5. Lipton RB, Liberman JN, Kolodner KB, Bigal ME, Dowson A, Stewart WF. Migraine headache disability and health-related quality-of-life: A population-based case-control study from England. Cephalalgia. 2003 23 : 441 450.
6. MacGregor EA, Brandes J, Eikermann A, Giammarco R. Impact of migraine on patients and their families: The Migraine And Zolmitriptan Evaluation (MAZE) survey - Phase III. Curr Med Res Opin. 2004 20 : 1143 1150.
7. Dueland AN, Leira R, Burke TA, Hillyer EV, Bolge S. The impact of migraine on work, family, and leisure among young women - A multinational study. Curr Med Res Opin. 2004 20 : 1595 1604.
8. Wober C, Brannath W, Schmidt K, et al. Prospective analysis of factors related to migraine attacks: The PAMINA study. Cephalalgia. 2007 27 : 304 314.
9. Granella F, Sances G, Pucci E, Nappi RE, Ghiotto N, Napp G. Migraine with aura and reproductive life events: A case control study. Cephalalgia. 2000 20 : 701 707.
10. Headache Classification Committee of the International Headache Society. The international classification of headache disorders: 2nd edition. Cephalalgia. 2004 24 (Suppl. 1 9 160.
11. MacGregor EA. Perimenstrual headaches: Unmet needs. Curr Pain Headache Rep. 2008 12 : 468 474.
12. MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology. 2006 67 : 2154 2158.
13. MacGregor EA, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neurology. 2004 63 : 351 353.
14. Couturier EG, Bomhof MA, Neven AK, van Duijn NP. Menstrual migraine in a representative Dutch population sample: Prevalence, disability and treatment. Cephalalgia. 2003 23 : 302 308.
15. Granella F, Sances G, Allais G, et al. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia. 2004 24 : 707 716.
16. Calhoun A, Ford S. Elimination of menstrual-related migraine beneficially impacts chronification and medication overuse. Headache. 2008 48 : 1186 1193.
17. Dowson AJ, Kilminster SG, Salt R, Clark M, Bundy MJ. Disability associated with headaches occurring inside and outside the menstrual period in those with migraine: A general practice study. Headache. 2005 45 : 274 282.
18. Stewart WF, Lipton RB, Chee E, Sawyer J, Silberstein SD. Menstrual cycle and headache in a population sample of migraineurs. Neurology. 2000 55 : 1517 1523.
19. Silberstein SD, Massiou H, McCarroll KA, Lines CR. Further evaluation of rizatriptan in menstrual migraine: Retrospective analysis of long-term data. Headache. 2002 42 : 917 923.
20. Diamond ML, Cady RK, Mao L, et al. Characteristics of migraine attacks and responses to almotriptan treatment: A comparison of menstrually related and nonmenstrually related migraines. Headache. 2008 48 : 248 258.
21. Silberstein SD, Massiou H, Le Jeunne C, Johnson-Pratt L, McCarroll KA, Lines CR. Rizatriptan in the treatment of menstrual migraine. Obstet Gynecol. 2000 96 : 237 242.
22. MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Prevention of menstrual attacks of migraine: A double-blind placebo-controlled crossover study. Neurology. 2006 67 : 2159 2163.
23. Tfelt-Hansen P, Block G, Dahlof C, et al. Guidelines for controlled trials of drugs in migraine: Second edition. Cephalalgia. 2000 20 : 765 786.
24. Serfling RJ. Approximation Theorems of Mathematical Statistics
25. Tepper SJ. Perimenstrual migraines: Are they different from migraines in general? Curr Pain Headache Rep. 2008 12 : 463 467.
26. Silberstein S. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee for the American Academy of Neurology. Neurology. 2000 55 : 754 762.